Lymphoblastic Leukemia clinical trials

Explore recruiting lymphoblastic leukemia clinical trials.

Recruiting lymphoblastic leukemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lymphoblastic Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

CAALL-F01: a French protocol for the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Single-center phase I/IIa study of infusion of autologous peripheral blood T cells expanded and genetically modified by Sleeping Beauty family transposons to express a chimeric antigen receptor with anti-CD19 specificity conjugated with the 4-1BB costimulatory region and CD3z and huEGFRt signal transmission (TranspoCART19) in patients with CD19+ acute lymphoblastic leukemia resistant or refractory to treatment

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

Germany, Sweden, Denmark, Italy, Austria, Czechia +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia

Ireland, Belgium, Spain, Sweden, Finland, Netherlands +7 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia with resistance, relapse or detectable measurable residual disease. Phase I/II clinical trial (MERMAID1)

Poland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia

Netherlands, Austria, Czechia, Denmark, Finland, Hungary +13 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Lymphoblastic Leukemia trials by city

Lymphoblastic Leukemia in Toronto Lymphoblastic Leukemia in Vancouver Lymphoblastic Leukemia in Montreal Lymphoblastic Leukemia in Calgary Lymphoblastic Leukemia in Edmonton Lymphoblastic Leukemia in Ottawa Lymphoblastic Leukemia in Winnipeg Lymphoblastic Leukemia in Quebec City Lymphoblastic Leukemia in Hamilton Lymphoblastic Leukemia in Kitchener Lymphoblastic Leukemia in London Lymphoblastic Leukemia in Halifax Lymphoblastic Leukemia in New York Lymphoblastic Leukemia in Los Angeles Lymphoblastic Leukemia in Chicago Lymphoblastic Leukemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease